Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmj.q2805 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eleven key measures for monitoring general practice clinical activity during COVID-19: A retrospective cohort study using 48 million adults' primary care records in England through OpenSAFELY.
Elife
July 2023
The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Article Synopsis
- - The COVID-19 pandemic significantly disrupted NHS primary care services, leading to the creation of the OpenSAFELY Service Restoration Observatory (SRO) to track clinical activity trends throughout this period.
- - An open-source data management framework was developed to analyze electronic health records from 48 million adults, focusing on key measures like blood pressure monitoring and asthma reviews from January 2019 to December 2021.
- - While most clinical activities showed signs of recovery by April 2021, some measures like medication and blood pressure reviews continued to experience notable reductions, indicating lasting impacts from the pandemic.
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence.
View Article and Find Full Text PDFWe assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combination with daratumumab (16 mg/kg per label) and dexamethasone (40 mg QW) (SDd) in patients with relapsed refractory multiple myeloma (RRMM). Thirty-four patients (median prior therapies, 3 [range, 2-10]) were enrolled; MM was refractory to proteasome inhibitor (PI) in 85%, immunomodulatory agent (IMiD) in 76%, both in 74%, and daratumumab in 6% of patients. Two dose-limiting toxicities (DLTs) were reported in the selinexor 60 mg twice-weekly cohort with no DLTs in the 100 mg QW cohort, making 100 mg QW the MTD and RP2D.
View Article and Find Full Text PDFA cheap fix for an expensive problem: the use of a thermoplastic mouthguard to reduce the risk of dental trauma during orotracheal intubation.
Anaesth Intensive Care
September 2016
VMO, Anaesthetics, Chris O'Brien Lifehouse, Sydney, NSW.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!